Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

Development of effective therapies for recurrent glioblastoma multiforme (GBM) and reliable, timely evaluation of their benefit are needed. Understanding the relationship between objective response (OR) and survival is important for determining whether OR can provide an early signal of treatment act...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Prados, Michael, Cloughesy, Timothy, Samant, Meghna, Fang, Liang, Wen, Patrick Y., Mikkelsen, Tom, Schiff, David, Abrey, Lauren E., Yung, W.K. Alfred, Paleologos, Nina, Nicholas, Martin K., Jensen, Randy, Vredenburgh, James, Das, Asha, Friedman, Henry S.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2011
Teme:
Clinical Investigations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018914/
https://ncbi.nlm.nih.gov/pubmed/21084434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq151
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items